Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions
Feb 19 (Reuters) - Texas Attorney General Ken Paxton on Thursday sued Sanofi SASY.PA for allegedly "bribing" providers to prescribe its medications over alternatives.
The attorney general's office issued a statement saying that the company created programs to offer services to healthcare providers, which it alleges amounted to bribes in violation of the Texas Health Care Program Fraud Prevention Act.
"These services are structured to comply with applicable federal and state laws and are intended to support patients, not to influence prescribing decisions," Sanofi said in a statement.
"The state's intervention has no bearing on the merits of this case, and Sanofi is zealously defending this litigation," Sanofi added.
Attorney General Paxton is seeking monetary relief of over a million dollars, including civil penalties, as well as an injunction to stop any further unlawful acts, the statement said.
The Attorney General has previously sued Sanofi and Bristol-Myers Squibb BMY.N for failing to disclose that their drug to prevent blood clots Plavix did not work effectively for certain patients.
Last year, Texas also sued Eli Lilly LLY.N for allegedly "bribing" providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound.
Related Articles
What Is the Best Nuclear Energy Investment in 2026? Which Should You Buy in, OKLO or Nuclear Energy ETFs?
TradingKey - Demand for electricity is surging, and data centers designed for artificial intelligence are a big reason. Governments are also demanding cleaner, dependable power. This coupling has brought about a revival in nuclear power, with capacity expected to increase in the coming decades. To i
Stock Market Crash 2026: What Fed Signals and Economic Data Mean for Investors
TradingKey - The possibility of a stock market crash occurring in 2026 is becoming increasingly likely as investor sentiment continues to decline.
New Fed Chair Warsh Takes Office: Major Shift in Monetary Policy? US Dollar Short-Term Rebound, 2026 Investment Strategy Analysis
TradingKey - At the start of 2026, global financial markets witnessed a major leadership change as U.S. President Trump officially nominated Kevin Warsh as the next Federal Reserve Chair. Pending Senate confirmation, he will succeed Jerome Powell this May to lead the world’s most influential central bank.
